Myosin heavy chain 9 (MYH9) mRNA (MYH9 mRNA)

Myosin heavy chain 9 (MYH9) mRNA encodes the non-muscle myosin heavy chain IIA (NMMHC-IIA), a motor protein essential for the eukaryotic cytoskeleton [UniProt P35579]. This protein plays a fundamental role in cytokinesis, cell migration, and the maintenance of cell shape and polarity across various tissues [NCBI Gene 4627]. While ubiquitously expressed, its function is particularly critical in megakaryocytes for proper platelet formation and in kidney podocytes for maintaining the glomerular filtration barrier [Pecci et al., 2018]. Mutations in the MYH9 gene lead to MYH9-related disease (MYH9-RD), a spectrum of autosomal dominant disorders characterized by macrothrombocytopenia and potential progression to renal failure, hearing loss, and cataracts [Pecci et al., 2018]. In oncology, MYH9 mRNA is often upregulated, promoting epithelial-mesenchymal transition (EMT) and increasing the metastatic potential of various cancer types [Ma et al., 2021]. Although small molecule inhibitors like blebbistatin target the MYH9 protein, the mRNA is an emerging therapeutic target for nucleic acid-based strategies, such as siRNA and antisense oligonucleotides, aimed at modulating its expression in pathological states like fibrosis and cancer [Ma et al., 2021]. However, the broad physiological importance of MYH9 necessitates highly specific delivery systems to avoid adverse effects on platelet and renal function [Freedman et al., 2009].

Other names

Non-muscle myosin heavy chain IIA mRNANMMHC-IIA mRNACellular myosin heavy chain, type A mRNANMMHC-A mRNA

RNA interference and antisense inhibition to reduce pathological protein expression.